Dr Reddys Laboratories Ltd
Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.
- Market Cap ₹ 1,12,116 Cr.
- Current Price ₹ 1,344
- High / Low ₹ 1,421 / 1,104
- Stock P/E 23.3
- Book Value ₹ 322
- Dividend Yield 0.60 %
- ROCE 25.2 %
- ROE 19.2 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 27.4% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 23.9%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of BSE Dividend Stability Index Nifty Healthcare Index Nifty India Manufacturing BSE Low Volatility Index Nifty 500 Multicap 50:25:25
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
8,370 | 9,728 | 10,011 | 10,292 | 9,720 | 9,359 | 10,626 | 11,850 | 13,349 | 14,405 | 16,962 | 19,484 | 21,745 | |
6,383 | 6,950 | 7,608 | 8,219 | 7,899 | 7,990 | 8,290 | 8,967 | 10,212 | 11,803 | 12,724 | 13,557 | 15,036 | |
Operating Profit | 1,987 | 2,778 | 2,403 | 2,073 | 1,820 | 1,370 | 2,336 | 2,883 | 3,137 | 2,602 | 4,238 | 5,926 | 6,710 |
OPM % | 24% | 29% | 24% | 20% | 19% | 15% | 22% | 24% | 24% | 18% | 25% | 30% | 31% |
140 | 135 | 211 | 317 | 516 | 164 | 202 | 730 | 801 | 474 | 568 | 862 | 866 | |
Interest | 61 | 78 | 64 | 64 | 57 | 63 | 57 | 48 | 47 | 38 | 17 | 22 | 47 |
Depreciation | 313 | 380 | 490 | 650 | 735 | 774 | 781 | 789 | 835 | 814 | 923 | 976 | 1,002 |
Profit before tax | 1,753 | 2,454 | 2,060 | 1,677 | 1,544 | 697 | 1,701 | 2,776 | 3,056 | 2,224 | 3,866 | 5,791 | 6,526 |
Tax % | 28% | 21% | 18% | 18% | 10% | 19% | 25% | -6% | 28% | 27% | 32% | 25% | |
1,266 | 1,933 | 1,679 | 1,374 | 1,384 | 567 | 1,277 | 2,938 | 2,186 | 1,623 | 2,613 | 4,342 | 4,809 | |
EPS in Rs | 14.90 | 22.73 | 19.71 | 16.11 | 16.70 | 6.83 | 15.38 | 35.36 | 26.29 | 19.51 | 31.38 | 52.06 | 57.66 |
Dividend Payout % | 20% | 16% | 20% | 25% | 24% | 59% | 26% | 14% | 19% | 31% | 26% | 15% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 13% |
3 Years: | 13% |
TTM: | 16% |
Compounded Profit Growth | |
---|---|
10 Years: | 8% |
5 Years: | 27% |
3 Years: | 32% |
TTM: | 26% |
Stock Price CAGR | |
---|---|
10 Years: | 8% |
5 Years: | 18% |
3 Years: | 13% |
1 Year: | 19% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 15% |
3 Years: | 14% |
Last Year: | 19% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 85 | 85 | 85 | 85 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 |
Reserves | 7,698 | 9,244 | 10,549 | 11,993 | 11,518 | 11,725 | 12,601 | 15,109 | 16,900 | 18,253 | 20,391 | 24,157 | 26,824 |
2,100 | 2,666 | 3,126 | 3,085 | 2,355 | 2,589 | 1,065 | 1,457 | 1,214 | 2,205 | 51 | 793 | 3,789 | |
2,106 | 2,513 | 2,696 | 2,422 | 2,491 | 2,704 | 2,499 | 2,827 | 3,431 | 3,954 | 4,850 | 5,326 | 5,963 | |
Total Liabilities | 11,989 | 14,508 | 16,456 | 17,585 | 16,447 | 17,100 | 16,248 | 19,476 | 21,630 | 24,496 | 25,375 | 30,359 | 36,660 |
2,387 | 2,748 | 3,249 | 4,438 | 4,842 | 4,717 | 4,683 | 4,434 | 5,844 | 6,150 | 7,195 | 7,589 | 7,900 | |
CWIP | 423 | 576 | 488 | 616 | 540 | 675 | 400 | 412 | 901 | 1,200 | 924 | 1,211 | 1,575 |
Investments | 2,379 | 2,806 | 3,862 | 5,076 | 3,102 | 3,636 | 3,934 | 5,486 | 4,649 | 4,937 | 7,440 | 7,321 | 12,502 |
6,800 | 8,377 | 8,856 | 7,455 | 7,963 | 8,072 | 7,231 | 9,145 | 10,235 | 12,208 | 9,815 | 14,239 | 14,682 | |
Total Assets | 11,989 | 14,508 | 16,456 | 17,585 | 16,447 | 17,100 | 16,248 | 19,476 | 21,630 | 24,496 | 25,375 | 30,359 | 36,660 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
289 | 906 | 1,786 | 2,747 | 1,016 | 1,539 | 2,762 | 1,839 | 3,514 | 1,339 | 5,053 | 3,450 | |
-524 | -874 | -2,031 | -1,919 | 1,430 | -1,180 | -546 | -1,689 | -1,454 | -1,990 | -3,403 | -3,429 | |
152 | 28 | 189 | -693 | -2,582 | -304 | -2,223 | -224 | -794 | 506 | -2,697 | 68 | |
Net Cash Flow | -84 | 60 | -56 | 135 | -135 | 54 | -8 | -74 | 1,266 | -146 | -1,047 | 89 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 129 | 171 | 172 | 138 | 165 | 164 | 128 | 143 | 112 | 125 | 92 | 87 |
Inventory Days | 217 | 233 | 223 | 234 | 256 | 258 | 242 | 224 | 250 | 242 | 219 | 291 |
Days Payable | 109 | 123 | 93 | 99 | 110 | 147 | 124 | 109 | 118 | 121 | 127 | 148 |
Cash Conversion Cycle | 237 | 281 | 302 | 273 | 311 | 274 | 246 | 257 | 243 | 247 | 184 | 230 |
Working Capital Days | 131 | 181 | 179 | 156 | 182 | 180 | 143 | 148 | 128 | 144 | 95 | 144 |
ROCE % | 20% | 23% | 16% | 12% | 11% | 5% | 12% | 19% | 15% | 12% | 19% | 25% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
2d - Allotment of shares on exercise of Employee Stock Options
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
10 Dec - Issuance of Letter of Confirmation for lost shares.
-
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
6 Dec - Dr. Reddy's subsidiary fined EUR 280 by Ukraine tax service.
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
5 Dec - Penalty of KZT 17.6 Mn imposed for tax disallowance.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
3 Dec - Schedule of analyst/investor meetings announced.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
Concalls
-
Nov 2024TranscriptPPTREC
-
Aug 2024TranscriptPPT
-
Jul 2024TranscriptPPT
-
May 2024TranscriptPPT
-
Feb 2024TranscriptPPT
-
Nov 2023TranscriptPPT
-
Jul 2023Transcript PPT
-
May 2023TranscriptPPT
-
Jan 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Jun 2022Transcript PPT
-
Feb 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
May 2021TranscriptPPT
-
May 2020TranscriptPPT
-
Jan 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
Apr 2017TranscriptPPT
-
Oct 2016TranscriptPPT
-
Jul 2016TranscriptPPT
-
Apr 2016TranscriptPPT
-
Nov 2015TranscriptPPT
Global Generics Segment (~83% of revenues in FY22)
Co. offers 400+ high-quality generic drugs, keeping costs reasonable by leveraging its integrated operations. The company benefits from its expertise in active ingredients, product development skills, a keen understanding of regulations and intellectual property rights & streamlined supply chain. [1]
Top revenue contributors of the segment are nervous system drugs (14%), gastrointestinal (13%) & anti-infective (10%) [2]
In FY22, co. filed 7 new ANDA’s with US FDA [3]